Pigmented Purpuric Dermatosis. Angioma serpiginosum
Conditions
Interventions
Intervention 1: Intervention group: Recipients of topical Heparin in gel form, 3000 IU/mg : In both groups, patients will be followed up three months after treatment initiation and two months after tr
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Informed consent Age over 18 years Clinical signs consistent with PPD, confirmed by skin biopsy and exclusion of other diseases with similar clinical presentations.
Exclusion criteria
Exclusion criteria: Lack of consent Pregnancy and breastfeeding Allergy to heparin or related products History (past or present) of HIT (Heparin-Induced Thrombocytopenia) and thrombosis Presence of open wounds, oozing eczema, or skin inflammation at the site of drug application (e.g., sunburn) Presence of infection or bleeding at the site of drug application History of any type of internal bleeding (e.g., cerebral or retinal hemorrhage) Previous treatment within the past six months History of peripheral vascular disease Use of anticoagulant medication History of blood disorders or bleeding abnormalities Diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome : Improvmentnof skin lesions in patients with PPD . Level 1: complete clearance of skin lesions ; Level 2 : more than 50% improvement; Level 3 : less than 50% improvement ; Level 4 : No response. Timepoint: 1) before starting treatment; 2) three months after starting treatment; 3) two months after stopping treatment. Method of measurement: Professional images of the affected skin areas will be reviewed by two independent dermatologists . To avoid overestimating the treatment efficacy, only responses classified as Level 1 and Level 2 will be used to calculate the response rate. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Karami
Tehran University of Medical Sciences
Outcome results
None listed